Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
Multiple sclerosis (MS)
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "Multiple sclerosis (MS)" in MCE Product Catalog:
Cat. No.: HY-B0194S
CAS No.: 1188331-19-2
Cat. No.: HY-P1996
CAS No.: 178823-49-9
Synonyms: NBI-5788
Target:
Research Areas:
Cat. No.: HY-P3724
CAS No.: 604803-17-0
Target:
Research Areas:
Cat. No.: HY-128879
CAS No.: 1281681-54-6
Target:
Research Areas:
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .
Cat. No.: HY-114898
CAS No.: 1826026-00-9
Target:
Research Areas:
ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .
Cat. No.: HY-12288R
CAS No.: 1306760-87-1
Synonyms: RPC-1063 (Standard)
Target:
Research Areas:
Ozanimod (Standard) is the analytical standard of Ozanimod. This product is intended for research and analytical applications. Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) .
Cat. No.: HY-D2902
CAS No.: 2080332-70-1
Target:
Research Areas:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
SNOTRAP (SNO trapping by triaryl phosphine) is a chemical probe used for detecting S-nitrosylated (SNO) proteins. SNOTRAP selectively converts S-nitrosylated cysteines in proteins into stable disulfide-iminophosphorane intermediates, which are then enriched with streptavidin and detected by nanoLC-MS/MS. SNOTRAP enables global enrichment and label-free quantification of SNO proteins and their modification sites in complex biological samples such as mouse brain tissues. SNOTRAP can be applied to studies related to nitrosative stress-associated diseases, including neurodegenerative diseases, cancer, and multiple sclerosis .
Cat. No.: HY-176731
Target:
Research Areas:
MSK-9 is a positive allosteric modulator of the P2X4 receptor with dual activities of enhancing ion conductance and delaying receptor inactivation. MSK-9 stabilizes the open state of the P2X4 receptor through rigid 3-piperidinyl and hydrophobic menthyl substituents. MSK-9 can be used in the study of multiple sclerosis (MS) .
Cat. No.: HY-P11299
CAS No.: 3082858-70-3
Target:
Research Areas:
Cat. No.: HY-P3541
CAS No.: 152074-97-0
Synonyms: MBP8298
Target:
Research Areas:
Cat. No.: HY-P10935
CAS No.: 1860001-61-1
Synonyms: 5-MP
Target:
Research Areas:
Cat. No.: HY-144126
CAS No.: 2760666-20-2
Target:
Research Areas:
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .
Cat. No.: HY-16622A
CAS No.: 1005407-76-0
Target:
Research Areas:
GSK1842799, an alkyl-substituted biaryl amino alcohol, is a selective S1P1 modulator developed for multiple sclerosis (MS). Upon phosphorylation, GSK1842799-P exhibited subnanomolar S1P1 agonist activity with over 1000-fold selectivity over S1P3. The compound showed good oral bioavailability, rapid in vivo conversion to GSK1842799-P, and significant lymphocyte count reduction at 0.1 mg/kg. It matched FTY720 efficacy at 3 mg/kg in the mouse EAE model and achieved comparable plasma levels to FTY-720 phosphate in cynomolgus monkeys. With favorable ADME, PK/PD properties, and toxicology, GSK1842799 advanced to further clinical development .
Cat. No.: HY-14977
CAS No.: 840523-39-9
Target:
Research Areas:
CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .
Cat. No.: HY-175984
Target:
Research Areas:
S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .
Cat. No.: HY-P1052
CAS No.: 118506-26-6
Target:
Research Areas:
Cat. No.: HY-P11127
CAS No.: 178328-64-8
Target:
Research Areas:
Cat. No.: HY-P1052A
Target:
Research Areas:
Cat. No.: HY-176784
CAS No.: 163913-87-9
Target:
Research Areas:
Human MOG-specifying DNA is located at chromosome 6 within the human leukocyte antigen (HLA) gene locus. Human MOG-specifying DNA is exclusively expressed in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocytes (ODCs) processes, with unique methylation patterns in ODCs. Human MOG-specifying DNA can be used for inflammatory demyelinating diseases such as multiple sclerosis (MS) research .
Cat. No.: HY-W062904
CAS No.: 248282-07-7
Synonyms: ABR-215062 sodium
Research Areas:
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
